Moreover, SRC and IGF1R were recently implicated in driving pancreatic ductal adenocarcinoma and melanoma resistance to pharmacologically or genetically targeted inhibition of ERK1/2 signaling through activating ERK5 (52, 53). This evidence concerns the gene MAPK7 and pancreatic ductal adenocarcinoma.